Examining Bladder Control Using Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)

August 17, 2017 updated by: Rahel Nardos, Oregon Health and Science University

Examining the Brain's Control Systems in Normal and Overactive Bladder Using DTI and Functional MRI

Urgency incontinence (where the bladder muscles contract suddenly, causing an immediate urge to urinate that is difficult to prevent) is commonly experienced in patients with overactive bladder. New findings have discovered that urgency incontinence may be connected to the interactions of certain regions of the brain and the bladder. Although this is a common problem, researchers still do not know how these interactions impact the process of urgency incontinence. The purpose of this study is to better understand how the brain functions, by using Magnetic Resonance Imaging (MRI) machine and Diffusion Tensor Imaging (DTI) to create images of the brain during different bladder states.

Study Overview

Status

Completed

Detailed Description

One devastating manifestation of overactive bladder is urgency incontinence. Although urgency incontinence is a common problem with profound clinical, social and psychological consequences, little is understood about its underlying cause. The involuntary detrusor overactivity (DO) often associated with the disease points to a possible abnormality in voluntary control of the spinobulbospinal voiding reflex by a higher order neuronal network. Recent functional MRI (fMRI) and PET studies have identified increased brain activity during bladder filling and voiding in normal subjects from higher order cognitive control centers. In addition, there are now data to suggest that interactions between these brain areas, which include the pontine micturition center (PMC), periaqueductal gray (PAG), thalamus, insula, dorsal anterior cingulate and prefrontal cortex, may be abnormal in patients with urgency incontinence. Despite these encouraging findings, we do not yet know how these regions are interacting with each other, or to other, unknown but important, regions in the brain. Nor do we know how this interaction might play a role in this disease process. Expanding our knowledge of how these regions are integrated to achieve continence and, importantly, what aspects of this complex circuitry are atypical in patients with urge incontinence is key to our future therapeutic endeavors. With this in mind, the goal of this study is to better characterize the functional integration (i.e. functional connectivity) of the brain's control networks in relation to typical and atypical bladder function. We aim to identify distinct differences in the brain's functional and anatomic topography in women with and without urgency incontinence. Our approach not only has the potential to advance our understanding of the higher level pathophysiology of this disease process, but could also lead to novel more centrally acting therapeutic approaches for treatment of urgency incontinence.

Study Type

Observational

Enrollment (Actual)

47

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women seeking care at Oregon Health and Science University in Portland, Oregon.

Description

CASE GROUP: This group will include 15 patients presenting to the urogynecology clinic at OHSU with current bladder overactivity symptoms including urgency and urgency incontinence with documented detrusor overactivity on multichannel urodynamic assessment.

Inclusion criteria:

  • Female urogynecology patients between age 40 and 85.
  • Without a history of incontinence surgery
  • Have current overactive bladder symptoms including urgency and urgency incontinence daily for the previous three months (must answer "about once a day to Question A1:how often do you leak urine, on initial screening questionnaire, and "3 or more months to question A2: How long have you experienced accidental leakage, and "yes" to question A3:Do you usually experience urinary leakage associated with feeling of urgency).
  • Documented detrusor overactivity by urodynamic study within 3 months of the study is required.
  • Patients who have a history of past anticholinergic therapy will be included as long as they have been off medication for 2 weeks prior to imaging.

Exclusion criteria:

  • Medical contraindications for MRI scanning.
  • Past or present overt neurological disease such as history of stroke, epilepsy, MS, spinal cord injury.
  • History of pelvic irradiation or bladder cancer.
  • Current urinary tract infection.
  • Current pelvic pain disorder.

CONTROL GROUP: This group will include 25 gynecology patients without a history of any urinary incontinence symptoms.

Inclusion Criteria:

  • Female gynecology patients between age 40 and 85.
  • Without a history of urinary incontinence (must answer "never" to question A1: how often do you leak urine, on initial screening questionnaire).
  • Without a history of incontinence surgery.
  • Without a history of overactive bladder.
  • Without pelvic pain.
  • Without irritative bladder symptoms (must say "no" to question A4: do you experience frequent urination on initial screening questionnaire).

Exclusion criteria:

  • Medical contraindications for MRI scanning.
  • Past or present overt neurological disease such as history of stroke, epilepsy, MS, spinal cord injury.
  • History of pelvic irradiation or bladder cancer.
  • Current urinary tract infection.
  • Current pelvic pain disorder.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Urge Incontinent Women
Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
Control Women
Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine differences in fluctuations in brain activity between different regions of the brain associated with control functions.
Time Frame: Once during up to 3 months
We will look at the overall group differences to see if there are differences between the case group participants and control group participants in control brain regions related to normal bladder function.
Once during up to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores on the Pelvic Floor Distress Inventory
Time Frame: Once during up to 3 months
This Questionnaire is a condition-specific quality of life questionnaire to assess pelvic floor disorders including urinary incontinence, pelvic organ prolapse and fecal incontinence.
Once during up to 3 months
3 Day Bladder Diary to Assess Participant Symptom Severity
Time Frame: Once during up to 3 months
Subjects will be given three questionnaires and will also be asked to keep a diary that tracks their bladder and urinary habits for 3 days.
Once during up to 3 months
Determine any difference in brain response to bladder filling in subjects with and without overactive bladder.
Time Frame: Once during up to 3 months
Once during up to 3 months
Determine functional brain connectivity with bladder.
Time Frame: Once during up to 3 months
In order to asses functional connectivity (measurement of the strength of integration between brain regions), direct statistical comparison of connectivity maps derived from urge incontinence versus control groups will be done.
Once during up to 3 months
Scores on the Pelvic Floor Impact Questionnaire
Time Frame: Once during up to 3 months
This is another validated brief quality of life questionnaire to assess how various pelvic floor disorders affect specific daily activities.
Once during up to 3 months
Scores on the International Consultation on Incontinence Questionnaire
Time Frame: Once during up to 3 months.
This questionnaire allows assessment of the prevalence, frequency and perceived cause of urinary incontinence as well as its impact on life.
Once during up to 3 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Rahel Nardos, M.D., Oregon Health and Science University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2010

Primary Completion (Actual)

June 22, 2012

Study Completion (Actual)

June 22, 2012

Study Registration Dates

First Submitted

April 16, 2010

First Submitted That Met QC Criteria

April 23, 2010

First Posted (Estimate)

April 26, 2010

Study Record Updates

Last Update Posted (Actual)

August 22, 2017

Last Update Submitted That Met QC Criteria

August 17, 2017

Last Verified

August 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence, Urge

3
Subscribe